Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Disease
- Therapeutic
- Assay
- Diagnostic
- Drug Discovery
- Molecular
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 240628
For Special Limitations Relating to Novel Annotation Proteins, the license grants with respect to each Novel Annotation Protein shall apply and be limited specifically to the CFA or CFAs which is/are the subject of the applicable Novel Utility (i.e., shall be limited to researching, developing, making, having made, importing, using, having used, offering for sale, selling and having sold products labeled for indications within the CFA or CFAs which is/are the subject of the applicable Novel Utility.
For Novel Utility Patents, Licensor shall have responsibility for deciding to file, preparing, filing and prosecuting patents applications relating to Novel Utility claims for Novel Annotation Proteins. From and after the date that a Novel Annotation Protein is designated as a QT, or from and after the date Licensor discovers a Novel Utility within an additional CFA during the ProgramTerm for such Novel Annotation Protein, the Parties shall mutually agree upon the data to be included in such patent applications in support of such Novel Utility and Licensor will advise Licensee of any material issues which arise during the prosecution of such patent applications in support of such Novel Utilities, and the Parties shall analyze the impact of such material issues.
Licensor shall have filed a patent application covering and claiming the Novel Utility of a Novel Annotation Protein at or prior to the designation of such Novel Annotation Protein as a QT.
Collaborative Focus Area means one or more of the following human diseases and/or conditions hematological diseases, oncology, cardiovascular diseases, pain, viral diseases, and with this amendment, effective as of !he Amendment Effective Date, urology, consisting of Urinary Incontinence and Benign Prostatic Hypertrophy (BPH).
IPSCIO Record ID: 240467
Restricted Targets.
With Respect to Returned QTs, Licensor grants a non-exclusive license in the Territory, under Licensors rights to Licensor Know-How and Patent Rights, to research, develop, make and use the Returned QTs and Configured Assays that embody or are based on such Returned QTs, to the extent necessary to discover or develop Licensee Royalty Products, and make, have made, import, use, have used, offer for sale, sell and have sold, in the Field, Licensee Royalty Products that are discovered or developed through the use of Returned QTs, subject, in the case of both, to any applicable field restrictions in the case of any Restricted Targets.
Cell-Based Assay means a Licensee Configured Assay that uses a QT incorporated in a cell or presented on the surface of a cell, as distinct from a biochemical assay in which the QT is assayed in a cell-free context.
Qualified Target or QT means a target for Small Molecule drug discovery identified or developed in the course of the Target Discovery Program that has all of the following characteristics
– is a Druggable Target that is a complete coding sequence of a human gene;
– has a Disease/Therapeutic Hypothesis;
– is either a Novel Protein, or fill Unrecognized Protein, or a Druggable Target that is otherwise approved by the Licensee Program Director as a Qualified Target; and
– the use of such target in the manner contemplated in the Research Plan would not, at the time of its identification or annotation in the Target Discovery Program, infringe one or more claims of an issued patent in the country in which such use of the target is expected to occur, unless such target is otherwise approved by the Licensee Program Director.
Non-Exclusive QT means a QT that has a Disease/Therapeutic Hypothesis in both a CFA and Non-CFA and that is designated by Licensor as a Non-Exclusive QT within seven (7) business days after such QT is entered into the QT Pool and a Licensor-Designated NonCFA means one Non-CFA that is associated, on the basis of a Disease/Therapeutic Hypothesis, with a QT, as designated by Licensor at the time such QT is designated a Non-Exclusive QT by Millennium.
'COLLABORATIVE FOCUS AREA' means one or more of the following human diseases and/or conditions (a) osteoporosis; (b) liver fibrosis; (c) hematological diseases and/or conditions (not including diseases and/or conditions excluded under subsections (d) and (e) below); (d) oncology, including, but not limited to, lung cancer, breast cancer, ovarian cancer and colon cancer, but excluding prostate cancer; (e) cardiovascular diseases and/or conditions, including, but not limited to, arrhythmia, abnormal hemodynamics, and hypertension, PROVIDED THAT the following diseases and/or conditions shall not be included (i) atherosclerosis (including the related diseases of thrombosis and restenosis); (ii) excessive clotting, and (iii) cardiomyopathy of any origin. (f) pain (including all therapies for relieving pain as distinct from curing or treating the underlying diseases or conditions that cause pain); and (g) viral diseases.
IPSCIO Record ID: 248009
– to research, develop, make and use any or all of the following in connection with the use of the Returned QT to discover or develop Small Molecule Drugs
(1) the Licensor Configured Assay that embodies or is based on a Returned QT, together with the standard operating procedures and reagents necessary, to use such Licensor Configured Assay for such purpose;
(2) if a Second Stage QT is designated as a Returned QT, the most promising lead structure under development by Licensor, and the optimization history of such lead structure and the data pertinent to critical optimization decisions that relate to such lead structure, the Second Stage Information, including without limitation, information on the major structural templates that were evaluated by Licensor and relevant SAR data; and
(3) if a Third Stage QT is designated as a Returned QT, the most promising lead structure under development by Licensor, and the optimization history of such lead structure and the data pertinent to critical optimization decisions that relate to such lead structure, the Third Stage Information, including without limitation, related SAR data, related pharmacological data, including toxicology and ADME information, and information related to chemical synthesis, provided, however, that, in the case of a Second Stage QT or a Third Stage QT, Licensor shall not be obligated to grant any such license with respect to the most promising lead structure if such lead structure is under development by Licensor as a Development Candidate or later stage drug candidate outside of the Licensor Development Program, in which event Licensor shall be obligated to grant such a license with respect to the next most promising lead structure that is not a Development Candidate or later stage drug candidate outside of the Licensor Development Program, and,
– to make, have made, import, use, have used, offer for sale, sell and have sold Small Molecule Drugs that are discovered or developed by Licensee through the use of Returned QTs.
This agreement includes exclusive and non-exclusive grants back to Licensor from Licensee.
Cell-Based Assay means a Licensor Configured Assay that uses a QT incorporated in a cell or presented on the surface of a cell, as distinct from a biochemical assay in which the QT is assayed in a cell-free context.
Qualified Target or QT means a target for Small Molecule drug discovery identified or developed in the course of the Target Discovery Program that has all of the following characteristics
– is a Druggable Target that is a complete coding sequence of a human gene;
– has a Disease/Therapeutic Hypothesis;
– is either a Novel Protein, or fill Unrecognized Protein, or a Druggable Target that is otherwise approved by the Licensor Program Director as a Qualified Target; and
– the use of such target in the manner contemplated in the Research Plan would not, at the time of its identification or annotation in the Target Discovery Program, infringe one or more claims of an issued patent in the country in which such use of the target is expected to occur, unless such target is otherwise approved by the Licensor Program Director.
Non-Exclusive QT means a QT that has a Disease/Therapeutic Hypothesis in both a CFA and Non-CFA and that is designated by Licensee as a Non-Exclusive QT within seven (7) business days after such QT is entered into the QT Pool and a Licensee-Designated NonCFA means one Non-CFA that is associated, on the basis of a Disease/Therapeutic Hypothesis, with a QT, as designated by Licensee at the time such QT is designated a Non-Exclusive QT by Millennium.